Ivermectin and Mebendazole Shows Clinical Benefits in Cancer Patients

Largest Real-World Analysis of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Regression

After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported no evidence of disease (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization.

Read full study here